Developing a Machine-Learning Prediction Model for Infliximab Response in Crohn’s Disease: Integrating Clinical Characteristics and Longitudinal Laboratory Trends Get access

• Abstract
• Lay summary
• Supplementary data

A Novel Serum Metabolomic Panel for the Diagnosis of Crohn’s Disease

• Abstract
• Lay summary
• Supplementary data

Network Clinical Collaboration to Improve Quality of Care of Patients With Inflammatory Bowel Disease in China

Risks of Cardiovascular Events in Patients With Inflammatory Bowel Disease in China: A Retrospective Multicenter Cohort Study

• Abstract
• Supplementary data

Alterations in Bile Acid Metabolism Associated With Inflammatory Bowel Disease

• Abstract
• Supplementary data

Fecal Microbiota Alterations Associated With Clinical and Endoscopic Response to Infliximab Therapy in Crohn’s Disease

• Abstract
• Supplementary data

Systematic Review and Meta-analysis: Short-Chain Fatty Acid Characterization in Patients With Inflammatory Bowel Disease Get access

• Abstract
• Supplementary data

Making Qualitative Intestinal Stricture Quantitative: Embracing Radiomics in IBD Get access

• Extract

Association of Infliximab Levels With Mucosal Healing Is Time-Dependent in Crohn’s Disease: Higher Drug Exposure Is Required Postinduction Than During Maintenance Treatment Get access

• Abstract
• Supplementary data

Cytokine IL9 Triggers the Pathogenesis of Inflammatory Bowel Disease Through the miR21-CLDN8 Pathway Get access

• Abstract
• Supplementary data

Serum Interleukin 9 Levels Predict Disease Severity and the Clinical Efficacy of Infliximab in Patients with Crohn's Disease Get access

• Abstract
• Supplementary data

P-107 Adalimumab Therapy Achieves Clinical Remission and Response at Week 26 in Chinese Patients with Crohn's Disease Get access

• Abstract

Opposite Effects of Interferon Regulatory Factor 1 and Osteopontin on the Apoptosis of Epithelial Cells Induced by TNF-α in Inflammatory Bowel Disease Get access

• Abstract